Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 4/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.66 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.66 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.55 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.55 |
| ▸ | BCHE | P06276 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5073629 | 0.88 | KDM4E (0.58) | CHRM2CHRM1CHRM3MTNR1AMTNR1B | |
| SCHEMBL18114970 | 0.84 | CHRM2 (0.77) | CHRM2CHRM1CHRM3TAAR1MTNR1A | |
| SCHEMBL3305893 | 0.83 | CHRM2 (0.59) | CHRM2CHRM1CHRM3TAAR1BCHE | |
| SCHEMBL30745170 | 0.83 | CHRM2 (0.59) | CHRM2CHRM1CHRM3TAAR1BCHE | |
| SCHEMBL5072956 | 0.83 | CNR1 (0.45) | CHRM2CHRM1CHRM3MEN1ALDH1A1 | |
| SCHEMBL417948 | 0.81 | TAAR1 (0.61) | CHRM2CHRM1CHRM3TAAR1MTNR1A | |
| SCHEMBL5212656 | 0.80 | BCHE (0.65) | BCHE | |
| SCHEMBL5543404 | 0.80 | CHRM2 (0.58) | CHRM2CHRM1CHRM3KDM4EMEN1 | |
| SCHEMBL9490930 | 0.80 | SLC2A1 (0.53) | CHRM2CHRM1CHRM3BCHEKDM4E | |
| SCHEMBL9517424 | 0.80 | CHRM2 (0.70) | CHRM2CHRM1CHRM3TAAR1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501830-B1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-10-05 | — | — | EP | claimed |
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| EP-1501830-A1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2005-02-02 | — | — | EP | claimed |
| WO-2003093267-A1 | 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-11-13 | — | — | WO | claimed |
| WO-2020249821-A1 | NOVEL ARGINASE INHIBITORS | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2020-12-17 | — | — | WO | disclosed |
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| US-20080312242-A1 | 7-ARYL-3, 9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS, LTD. (CH) | 2008-12-18 | — | — | US | disclosed |
| US-7427613-B2 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-09-23 | — | — | US | disclosed |
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-08-11 | — | — | US | disclosed |
| US-5648540-A | Amine preparation | NPS PHARMACEUTICALS, INC. (US) | 1997-07-15 | — | — | US | disclosed |
| US-5633404-A | N-((R)-α-methyl-3-methoxybenzyl)-3-(2-chlorobenzene)propanamide | NPS PHARMACEUTICALS, INC. (US) | 1997-05-27 | — | — | US | disclosed |
| WO-1996029309-A1 | N-ACYLPIPERIDINYLCARBONYLAMINOCARBOXYLIC ACIDS AND THEIR USE AS GLYCOPROTEIN IIB/IIa ANTAGONISTS AND FIBRINOGEN-BLOOD PLATELETS BINDING INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-09-26 | — | — | WO | disclosed |
| WO-1996002492-A1 | METHOD OF MAKING A BENZYLPROPANAMINE | NSP PHARMACEUTICALS, INC. (US) | 1996-02-01 | — | — | WO | disclosed |
| EP-0669912-A1 | N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-06 | — | — | EP | disclosed |
| WO-1995008536-A1 | N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-30 | — | — | WO | disclosed |
| US-5231181-A | PROCESS FOR THE PREPARATION OF (8AS,12AS,13AS)-DECAHYDROISOQUINO ((2,1-G) (1,6)-NAPHTHYRIDIN-8-ONE DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1993-07-27 | — | — | US | disclosed |
| EP-0505183-A2 | Process for the preparation of (8aS,12aS,13aS)-decahydroisoquino[2,1-g][1,6]-naphthyridin-8-one derivatives | SYNTEX (U.S.A.) INC. (US) | 1992-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, CHRM1, SRMS | CHRM2 6/4885CHRM1 2/4885CHRM3 30/4885 |
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | REN, AGTR1, ACE | CHRM2 3509/4885CHRM1 2464/4885CHRM3 2273/4885 |
| US-20080312242-A1 | 7-ARYL-3, 9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | REN, AGTR1, ACE | CHRM2 3509/4885CHRM1 2464/4885CHRM3 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.